Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • Tauroursodeoxycholate Pinquart M Duberstein PR Information n

    2020-08-12

    [11] Pinquart M, Duberstein PR. Information needs and decision-making processes in older cancer patients. Crit Rev Oncol Hematol 2004;51(1):69–80. [12] Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the “silver tsunami”: preva-lence trajectories and comorbidity burden among older Cancer survivors in the United States. Cancer Epidemiol Biomarkers Prev 2016;25(7):1029–36.
    [13] Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer inci-dence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009;27(17):2758–65. [14] Blanchard CG, Labrecque MS, Ruckdeschel JC, Blanchard EB. Physician behaviors, pa-tient perceptions, and patient characteristics as predictors of satisfaction of hospital-ized adult cancer patients. Cancer 1990;65(1):186–92.
    [16] Davidson R, Mills ME. Cancer patients' satisfaction with communication, information and quality of care in Tauroursodeoxycholate UK region. Eur J Cancer Care (Engl) 2005;14(1):83–90. [17] Pope CR, Russell AA. Measuring patient satisfaction: a post-visit survey vs a general membership survey. HMO Pract 1997;11(2):74–9. [18] Rahmqvist M. Patient satisfaction in relation to age, health status and other back-ground factors: a model for comparisons of care units. International J Qual Health Care 2001;13(5):385–90. [19] Fitch MI, Gray RE, Franssen E. Perspectives on living with ovarian cancer: older women's views. Oncol Nurs Forum 2001;28(9):1433–42. [20] Greene MG, Adelman RD. Physician-older patient communication about cancer. Pa-tient Educ Couns 2003;50(1):55–60. [21] Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds in-formation to eastern cooperative oncology group performance status in elderly can-cer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002;20(2): 494–502.
    [22] Elliott MN, Beckett MK, Lehrman WG, et al. Understanding the role played by Medicare's patient experience points system in hospital reimbursement. Health Aff (Millwood) 2016;35(9):1673–80.
    [23] Rocque GB, Partridge EE, Pisu M, et al. The patient care connect program: transforming health care through lay navigation. J Oncol Pract 2016;12(6):e633–42. [24] Jean-Pierre P, Fiscella K, Freund KM, et al. Structural and reliability analysis of a pa-tient satisfaction with cancer-related care measure: a multisite patient navigation research program study. Cancer 2011;117(4):854–61.
    [29] Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med 2000;19(22):3127–31. [30] Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. L. Erlbaum As-sociates: Hillsdale, N.J; 1988. [31] Walsh J, Harrison JD, Young JM, Butow PN, Solomon MJ, Masya L. What are pelagic zone the cur-rent barriers to effective cancer care coordination? A qualitative study. BMC Health Serv Res 2010;10:132. [32] Ellis PM. The importance of multidisciplinary team management of patients with non-small-cell lung cancer. Curr Oncol 2012;19(Suppl. 1):S7–s15. [33] Ren XS, Kazis L, Lee A, Rogers W, Pendergrass S. Health status and satisfaction with health care: a longitudinal study among patients served by the veterans health ad-ministration. Am J Med Qual 2001;16(5):166–73.
    [34] Moore AD, Hamilton JB, Knafl GJ, et al. The influence of mistrust, racism, religious participation, and access to care on patient satisfaction for African American men: the North Carolina-Louisiana prostate cancer project. J Natl Med Assoc 2013;105 (1):59–68.
    [35] Siminoff LA, Graham GC, Gordon NH. Cancer communication patterns and the influ-ence of patient characteristics: disparities in information-giving and affective behav-iors. Patient Educ Couns 2006;62(3):355–60. [36] Fenton JJ, Jerant AF, Bertakis KD, Franks P. The cost of satisfaction: a national study of patient satisfaction, health care utilization, expenditures, and mortality. Arch Intern Med 2012;172(5):405–11.
    Contents lists available at ScienceDirect
    Journal of Pharmaceutical and Biomedical Analysis
    An immunosensing device based on inhibition of mediator’s faradaic process for early diagnosis of prostate cancer using bifunctional nanoplatform reinforced by carbon nanotube
    Leila Farzin a,∗ , Sodeh Sadjadi b, Mojtaba Shamsipur c,∗ , Shahab Sheibani a
    a Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran b Material and Nuclear fuel school, Nuclear Science and Technology Research Institute, Tehran, Iran c Department of Chemistry, Razi University, Kermanshah, Iran
    Article history:
    Keywords:
    Histidine-rGO